Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Sarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cytarabine 6Thioguanine 4Methotrexate 4Idarubicin 4Etoposide 4Daunorubicin 4Azacitidine 4Peripheral Blood Stem Cell Transplantation 3Early Intervention, Educational 3Decitabine 3Cyclophosphamide 3liposomal amphotericin B 2decitabine and cedazuridine drug combination 2Therapeutics 2Radiotherapy 2Psychiatric Rehabilitation 2ON 01910 2Mitoxantrone 2Hydrocortisone 2Filgrastim 2Dexamethasone 2Busulfan 2Biopsy 2Asparaginase 2valspodar 1sabatolimab 1pevonedistat 1palmitoyl-L-asparaginase 1merphos 1lonafarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelomonocytic, Chronic × glasdegib × Clear all
NCT04842604 2023-12-18

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Pfizer

Phase 3 Completed
14 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡